IMMOMEC

IMmune MOdulating strategies for treatment of MErkel cell Carcinoma

 Coordinatore Medizinische Universitaet Graz 

 Organization address address: AUENBRUGGERPLATZ 2
city: GRAZ
postcode: 8036

contact info
Titolo: Prof.
Nome: Juergen
Cognome: Becker
Email: send email
Telefono: 4331640000000
Fax: 4331640000000

 Nazionalità Coordinatore Austria [AT]
 Sito del progetto http://immomec.eu/
 Totale costo 7˙426˙212 €
 EC contributo 5˙717˙979 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2011-two-stage
 Funding Scheme CP-FP
 Anno di inizio 2012
 Periodo (anno-mese-giorno) 2012-01-01   -   2016-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    Medizinische Universitaet Graz

 Organization address address: AUENBRUGGERPLATZ 2
city: GRAZ
postcode: 8036

contact info
Titolo: Prof.
Nome: Juergen
Cognome: Becker
Email: send email
Telefono: 4331640000000
Fax: 4331640000000

AT (GRAZ) coordinator 542˙698.86
2    PHILOGEN SPA

 Organization address address: PIAZZA LA LIZZA 7
city: SIENA
postcode: 53100

contact info
Titolo: Dr.
Nome: Chiara
Cognome: Falciani
Email: send email
Telefono: +39 0577 234928

IT (SIENA) participant 2˙171˙625.00
3    IMMATICS BIOTECHNOLOGIES GMBH

 Organization address address: PAUL EHRLICH STR 15
city: TUEBINGEN
postcode: 72076

contact info
Titolo: Mr.
Nome: Mark
Cognome: Bleckmann
Email: send email
Telefono: +49 7071 5397700
Fax: +49 7071 5397900

DE (TUEBINGEN) participant 858˙712.00
4    UNIVERSITAETSKLINIKUM ESSEN

 Organization address address: HUFELANDSTRASSE 55
city: ESSEN
postcode: 45147

contact info
Titolo: Mr.
Nome: Sebastian
Cognome: George
Email: send email
Telefono: 492017000000
Fax: 492017000000

DE (ESSEN) participant 691˙837.60
5    REGION HOVEDSTADEN

 Organization address address: KONGENS VAENGE 2
city: HILLEROD
postcode: 3400

contact info
Titolo: Dr.
Nome: Uööa Hoy
Cognome: Davidsen
Email: send email
Telefono: +45 3868 4718

DK (HILLEROD) participant 503˙948.46
6    MARIA SKLODOWSKA-CURIE MEMORIAL CANCER CENTER

 Organization address address: "Ul.W.K. Roentgena, 5"
city: WARZAWA
postcode: 2781

contact info
Titolo: Prof.
Nome: Piotr
Cognome: Rutkowski
Email: send email
Telefono: 48226439375

PL (WARZAWA) participant 189˙546.48
7    ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

 Organization address address: 3 Avenue Victoria
city: PARIS
postcode: 75004

contact info
Titolo: Ms.
Nome: Anne
Cognome: Skrobot
Email: send email
Telefono: 33144841783
Fax: 33144841788

FR (PARIS) participant 189˙546.46
8    CHARITE - UNIVERSITAETSMEDIZIN BERLIN

 Organization address address: Chariteplatz 1
city: BERLIN
postcode: 10117

contact info
Titolo: Ms.
Nome: Eveline
Cognome: Fräßdorf
Email: send email
Telefono: +49 30 450 576024
Fax: +49 30 450576954

DE (BERLIN) participant 189˙546.46
9    EBERHARD KARLS UNIVERSITAET TUEBINGEN

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Prof.
Nome: Claus
Cognome: Garbe
Email: send email
Telefono: +49 7071 2987110

DE (TUEBINGEN) participant 189˙546.46
10    FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA

 Organization address address: CARRER ROSSELLO 149-153
city: BARCELONA
postcode: 8029

contact info
Titolo: Ms.
Nome: Pastora
Cognome: Martinez Samper
Email: send email
Telefono: +34 932 275 707
Fax: +34 932 279 205

ES (BARCELONA) participant 189˙546.46
11    THE UNIVERSITY OF NOTTINGHAM

 Organization address address: University Park
city: NOTTINGHAM
postcode: NG7 2RD

contact info
Titolo: Mr.
Nome: Jill
Cognome: Burton
Email: send email
Telefono: +44 115 8466757

UK (NOTTINGHAM) participant 1˙424.76

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

cell    predictive    mortality    monitor    merkel    identification    therapies    rare    therapeutic    therapy    disease    prognostic    melanoma    cancer    rate    immomec    treatment    immunotherapy    cancers    mcc    patients    lethal    modulating    biomarkers    metastatic    skin    solid    strategies    carcinoma    immune   

 Obiettivo del progetto (Objective)

'Merkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer of the skin associated with the recently discovered, common Merkel cell polyomavirus (MCV). With an incidence of 0.44 per 100,000 MCC is a very rare cancer. Notably, however, although MCC is 40 times less common than malignant melanoma, MCC has a dramatically higher mortality rate than melanoma rendering MCC to the most lethal skin cancer (37 versus 15 percent). This high mortality rate is largely due to the fact that to date none of the currently available therapeutic interventions is able to improve overall survival of patients suffering from metastatic disease. Consequently, new therapeutic strategies are needed for metastatic MCC. Since several lines of evidence indicate the outstanding immunogenicity of MCC, immune modulating treatment strategies are particularly attractive. IMMOMEC is a 5-year project to establish and investigate an innovative and effective immunotherapy for MCC, thus directly responding to the aims of the topic HEALTH-2011.2.4.1-1 Investigator-driven treatment trials for rare cancers. IMMOMEC will develop a rational immune therapeutic approach for treatment of patients with MCC that is based on the targeted delivery of interleukin-2 to the tumor microenvironment. However, IMMOMEC will not only provide a new therapeutic option for MCC patients, but will also establish the relevance of immune modulating strategies to treat solid cancers in general, establish and validate new tools to monitor patients receiving such therapies as well as compile prognostic and predictive biomarkers to individualize immune modulating therapies. Moreover, IMMOMEC will introduce a new immune modulating therapeutic produced by a European SME, which also holds the intellectual property rights.

Objectives of IMMOMEC: I. Establish an effective therapy for Merkel cell carcinoma evaluated in a multicentre randomized clinical phase II trial II. Establish the feasibility of effective immunotherapy for solid cancers III. Identification and characterization of HLA-restricted immunodominant T cell epitopes specific for MCC to monitor the immune modulating effect and to develop specific therapeutics IV. Identification of prognostic and predictive biomarkers, i.e. search for markers foretelling the course of disease or treatment response in MCC, respectively V. Establish a European network for research and therapy of MCC'

Altri progetti dello stesso programma (FP7-HEALTH)

INFARCT CELL THERAPY (2009)

Therapy after heart infarct: prevention of reperfusion injury and repair by stem cell transfer

Read More  

A-PARADDISE (2014)

Anti-Parasitic Drug Discovery in Epigenetics

Read More  

DRUGSFORD (2012)

Preclinical development of drugs and drug delivery technology for the treatment of inherited photoreceptor degeneration

Read More